A Phase 1 Study of MM-141 in Patients with Advanced Solid Tumors

Trial Profile

A Phase 1 Study of MM-141 in Patients with Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Istiratumab (Primary) ; Everolimus; Gemcitabine; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2016 Results of this trial, presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2015 Planned primary completion date changed from 1 Aug 2014 to 1 May 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top